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In the face of the current obesity epidemic, the nature of the relationship between overnutrition and type 2
diabetes is of great importance. Obesity can be considered a state of excessive insulin action that elicits
a series of cellular homeostatic responses, producing systemic insulin resistance. These responses occur
in four steps: homologous desensitization to insulin action, leptin secretion, inflammation, and, finally,
a counter-inflammatory phase that serves to conserve energy storage. The molecular mechanisms under-
lying these steps are discussed in the context of potential new therapeutic approaches.It will not come as a shock to the reader that we are in themidst of
a major worldwide epidemic of obesity and type 2 diabetes. The
numbers are staggering, and with over 1.5 billion people now
obese or overweight, the eventual impact of expected complica-
tions are predicted to take amajor toll on public health (Swinburn
et al., 2011; Wang et al., 2011b). The reasons for this epidemic
remain obscure; several hypotheses have emerged, including
increased food availability, adaptation to a sedentary lifestyle,
changes in food content or nutritional value, intestinal dysbiosis,
viral infection, low or high birth weight, evolutionary pressure, or
all of the above. While I will leave it to others to sort through the
origins of this phenomenon, one aspect is certain: the increased
occurrence of metabolic disease can be traced to a positive
energy balance in individuals.
What controls energy homeostasis in the face of excess
caloric intake? It is well established that insulin is the major
anabolic physiological agent and master regulator of energy
storage (Saltiel and Kahn, 2001; Taniguchi et al., 2006). Upon
ingestion of protein or carbohydrate, insulin is released from
the b cells of the pancreas and, in turn, activates its receptor
on fat, muscle and liver cells, increasing glucose, amino acid,
and fatty acid uptake and storage, and also blocking breakdown.
Insulin thus ensures efficient storage of energy so that it is avail-
able for mobilization during fasting, when insulin levels are low.
However, chronic overnutrition, undernutrition, or other states
of cellular stress can generate insulin resistance (Biddinger and
Kahn, 2006; Doria et al., 2008; Olefsky and Glass, 2010; Saltiel,
2001), which is advantageous when energy mobilization is
needed. Numerous longitudinal and crosspopulation studies
have indicated a strong correlation between obesity and insulin
resistance and, similarly, between insulin resistance and dia-
betes (Reaven, 2005a, 2005b; Stumvoll et al., 2005). Augmented
synthesis and secretion of the hormone and expansion of b cell
mass counter the increased demand for insulin until b cells can
no longer compensate. Taken together, these observations
suggest a linear pathway to type 2 diabetes, wherein overnutri-
tion and excess energy accumulation in adipocytes, myocytes,
and hepatocytes triggers signals that lead to insulin resistance
and, finally, decreased insulin secretion.
Drilling down into the cause of type 2 diabetes has been diffi-
cult, and whether there is indeed a teleological explanation for
the development of insulin resistance in obesity is unknown.798 Cell Metabolism 15, June 6, 2012 ª2012 Elsevier Inc.Nevertheless, several questions face us. Why does insulin resis-
tance develop after obesity or overnutrition, and how is it gener-
ated? Is insulin resistance cell-autonomous or is it a concerted
effect of tissue crosstalk? How does obesity persist in the face
of insulin resistance? I propose here that insulin resistance is
the physiological response of cells to stressful situations in which
it is advantageous tomobilize rather than store energy. One such
situation is overnutrition, which is essentially a state of excessive
insulin action. Thus, insulin resistance is a homeostatic response
that reaches a pathological state as it becomes systemic and
sustained. Furthermore, I propose that there are multiple,
sequential stages by which this homeostatic response occurs.
Outlined here are four steps in the defense against obesity
(Figure 1). These steps include homologous desensitization of
insulin signaling pathways, secretion of the adipostat leptin,
generation of chronic inflammation, and, finally, counterinflam-
mation, during which the evolutionary pressure to store energy
eventually overcomes insulin resistance by co-opting insulin
signaling pathways, so that insulin resistance fails as a response
to limit obesity. Although I concede that this is an oversimplifica-
tion of a complex process and does not take into account many
aspects of receptor signaling, appetite regulation, genetics,
b cell biology, and innate immunity, it is put forth as an over-
arching hypothesis in an attempt to unify some of the perplexing
questions regarding obesity and insulin resistance.
Step 1. Homologous Desensitization to Insulin Action
Homeostasis is a universal attribute of biological systems. Not
surprisingly, homeostatic mechanisms exist to prevent fat,
liver, and muscle cells from the overaccumulation of energy
substrates. In the short term, once insulin target cells have
reached a threshold, insulin-dependent energy storage is atten-
uated via acute feedback pathways that impinge on the insulin
receptor to decrease its coupling to downstream targets
(Figure 2). This kind of homologous desensitization is likely to
occur via several mechanisms, including downregulation of the
insulin receptor (Bar et al., 1979; Carpentier et al., 1985),
increased expression or activity of protein tyrosine phospha-
tases that can inactivate the receptor or its substrates (Yip
et al., 2010), or activation of phosphoinositide phosphatases,
such as PTEN, SHIP2, or myotubularin that reduce levels of
signaling phosphoinositides (Lazar and Saltiel, 2006).
  
 
 
 
 
 
Figure 1. The Four-Step Response to Obesity
Figure 2. Step 1: Homologous Desensitization
Insulin increases nutrient uptake and storage as lipid in adipocytes through
different pathways, including Akt and mTORC1. After sustained activation of
its receptor, insulin signaling is downregulated through several mechanisms,
including reduced cell-surface expression of its receptor, increased activity of
tyrosine phosphatases (PTPases) and inositol lipid phosphatases (PIPases),
and retrophosphorylation of insulin receptor substrates, reducing their tyrosine
phosphorylation. Lipid accumulation can also produce substrate retro-
phosphorylation via PKC’s.
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from retrophosphorylation events that reduce signaling from
the receptor (Zick, 2005). Insulin receptor signaling is initiated
upon the tyrosine phosphorylation of intracellular substrates,
particularly the insulin receptor substrate (IRS) family of proteins.
These tyrosine phosphorylation events are attenuated when IRS
proteins are serine phosphorylated. This occurs on a number of
sites, due to the activities of several different protein serine
kinases (Aguirre et al., 2002; Hotamisligil et al., 1996; Zick,
2005). Some of these are stimulated by insulin itself, including
the MAP kinase ERK, mTORC1, and S6 kinase. Thus, insulin
can produce a negative feedback loop that diminishes the
activity of a lipogenic or glycogenic pathway, representing the
first line of defense against excessive insulin action.
Negative feedback in insulin signaling can also acutely result
from lipogenesis. Several studies have demonstrated that diac-
ylglycerides, in particular, lead to activation of protein kinase C
isoforms that may also catalyze serine phosphorylation of IRS
proteins, resulting in their decreased tyrosine phosphorylation
(Kim et al., 2004). It is possible that this phenomenon explains
the acute insulin resistance that has been observed upon lipid
infusion in rodents or humans, which may be a model of short-
term receptor desensitization (Itani et al., 2002; Samuel et al.,
2010; Savage et al., 2007).
Step 2. Leptin as an Adipostat
Perhaps the most important discovery of the last quarter century
in metabolic research concerns the role of leptin as a feedback
regulator of energy storage (Friedman, 2004; Friedman and Ha-
laas, 1998), thus exposing the role of adipocytes as endocrine
cells (Figure 3). Although leptin is not the only counterregulatory
hormone for insulin, it stands alone as an adipostat that
responds directly to energy status in the adipocyte (Badman
and Flier, 2007). Although the molecular mechanisms involved
in the regulation of leptin synthesis and secretion have not
been elucidated, there is clear evidence that levels of the
hormone fall during starvation and are elevated with feeding
(Spiegelman and Flier, 2001). Once released into the circulation,
leptin acts on receptors, located primarily in the hypothalamus,to produce three major effects that are catabolic and, thus,
directly opposed to insulin action. First, leptin represses appe-
tite, reducing nutrient intake and availability (Spiegelman and
Flier, 2001). Second, acting via the sympathetic nervous system,
leptin increases activity of the hepatic AMP-activated protein
kinase (AMPK), producing a cascade of phosphorylation events
that results in reduced lipogenesis and increased fatty acid
oxidation (Kahn et al., 2005; Minokoshi et al., 2002). Finally,
sympathetic activation also causes increased b-adrenergic
activity in both brown and white fat cells, stimulating lipolysis
and expression of uncoupling protein 1, thus coordinately
increasing fatty acid generation from triglyceride and oxidation
via cAMP production (Collins et al., 1996; Halaas et al., 1997;
Rosenbaum and Leibel, 2010).
Although leptin is perhaps the most potent anorexic hormone
that responds directly to nutritional status, states of obesity in
both humans and rodents are commonly associated with leptin
resistance and high leptin levels (Myers et al., 2010). As such,
leptin has not proven to be an effective anti-obesity agent in
obese patients (Tam et al., 2011). However, when administered
to mice (Halaas et al., 1995; Pelleymounter et al., 1995) or to
patients with mutations in the leptin gene (Farooqi et al., 2007)
or lipodystrophy (Oral et al., 2002), the hormone not only
reverses obesity, but also has profound antidiabetic effects
with dramatically improved insulin resistance. This illustrates
well the apparent paradox in which insulin resistance can be
overcome by administration of an agent that effectively opposes
insulin action. Likewise, metformin and other biguanides mimic
part of leptin’s indirect action in the liver by activating AMP-acti-
vated kinase (AMPK) (Hardie, 2003; Zhou et al., 2001), whereas
b3 adrenergic agonists can mimic leptin’s indirect actions at
the adipocyte by increasing lipolysis and fat oxidation (Grujic
et al., 1997). Both agents improve insulin resistance, even
though they act in a manner that is diametrically opposed to
the anabolic effects of the hormone.Cell Metabolism 15, June 6, 2012 ª2012 Elsevier Inc. 799
Figure 4. Step 3: Inflammation
As leptin resistance occurs, the adipocyte continues to expand and store lipid.
At some point, through mechanisms that are not well understood, chemo-
kines, such as MCP1, are released that recruit M1-polarized proinflammatory
macrophages to adipose tissue. These macrophages, in turn, secrete TNF-a,
IL-6, and other proinflammatory cytokines that bind to receptors on adipo-
cytes. At the same time, Toll receptors are activated, perhaps in response to
local increases in fatty acids. Together, these receptors initiate MAP kinase
pathways that increase lipolysis and desensitize insulin action via the mech-
anisms described in Figure 2.
Figure 3. Step 2: Leptin as an Adipostat
Adipocytes sense size or lipid stores through an unknown mechanism and, in
turn, secrete the hormone leptin. Leptin binds to receptors in the hypothal-
amus, which activates neuronal pathways that 1) reduce appetite; 2) activate
hepatic fatty acid oxidation while reducing lipogenesis; and 3) increase
sympathetic activity, resulting in release of norepinephrine to activate the
b-adrenergic receptors in adipocytes.
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Although receptor desensitization and leptin both oppose insulin
action to limit excess energy accumulation, the development of
leptin resistance and other adaptive responses ensures that
energy storage continues in the face of continued overnutrition.
It is difficult to ascertain the precise temporal relationship of
these different biological events (Lee et al., 2011), but careful
high-fat diet feeding studies in rodents suggest that the next
line of defense against obesity is inflammation (Li et al., 2010b;
Olefsky and Glass, 2010). Compelling evidence has accrued
that both genetic and dietary forms of rodent obesity are accom-
panied by generation of a low-grade inflammation in adipose and
liver tissue (Gregor and Hotamisligil, 2011; Hotamisligil, 2010;
Lumeng and Saltiel, 2011). Moreover, there is now considerable
reason to conclude that in many cases the generation of inflam-
mation may be a key link between obesity and sustained insulin
resistance. Almost all rodent models of obese insulin resistance
are associated with chronic inflammation, and there has been
a strong correlation between insulin resistance and inflammatory
markers in studies of several patient groups (Aron-Wisnewsky
et al., 2009; Blackburn et al., 2006; Festa et al., 2002; Pradhan
et al., 2001). This inflammation is generally low-grade and
accompanied by macrophage switching from a type 2 to
type 1 polarization state (Lumeng et al., 2007a; Odegaard and
Chawla, 2011; Schenk et al., 2008), as well as the presence of
additional inflammatory cells (Feuerer et al., 2009; Nishimura
et al., 2009; Winer et al., 2009, 2011). Additionally, coculture
studies (Lumeng et al., 2007b) using neutralizing antibodies
directed against different proinflammatory cytokines have
demonstrated in vitro that inflammatory signals can desensitize
cells to insulin via different mechanisms. Inhibition of inflamma-
tory signaling by knockout of key pathways in obese mice,
including components of NF-kB (Arkan et al., 2005) and JNK
(Hirosumi et al., 2002) pathways, as well as numerous other
proinflammatory signaling molecules, scaffolding proteins, and800 Cell Metabolism 15, June 6, 2012 ª2012 Elsevier Inc.cytokines, can disrupt the link between obesity and insulin
resistance (Holland et al., 2007; Hotamisligil, 2010; Lesniewski
et al., 2007; Nakamura et al., 2010; Saberi et al., 2009;
Shi et al., 2006; Summers, 2010; Vandanmagsar et al., 2011;
Wellen et al., 2007). Likewise, different anti-inflammatory phar-
macological approaches can also reduce insulin resistance in
rodents (Hundal et al., 2002), and recent data indicates that
the NF-kB inhibitor salsalate may produce antihyperglycemic
effects in patients (Goldfine et al., 2010).
The molecular underpinnings of obesity-induced inflammation
have been studied extensively. Proinflammatory adipose tissue
macrophages (ATMs) infiltrate fat during the later stages of
obesity (Figure 4). Alterations in ATM content and polarization
state appear to occur coincident with the development of insulin
resistance, but evidence has accumulated that other changes in
the innate immune systemmay precede these events, and ATMs
may be effectors of a coordinated inflammatory response that
includes the accumulation of Th1 polarized CD4+ T cells and
the loss of Tregs, as well as the appearance of B cells, NK cells,
NKT cells, eosinophils, neutrophils, and mast cells (Lumeng and
Saltiel, 2011; Olefsky and Glass, 2010).
The primary signals in adipocytes and hepatocytes that trigger
this inflammatory response remain a point of contention. Studies
have implicated ER stress (Hotamisligil, 2010), adipose tissue
hypoxia (Hosogai et al., 2007), enhanced lipolysis (Kosteli
et al., 2010), and adipocyte death (Cinti et al., 2005). However,
although blocking these signals in some cases may prevent
inflammation and development of sustained insulin resistance,
these changes occur fairly late in the progression of the disease
and probably are not initiating events. In this regard, a leading
hypothesis for how inflammation is initiated from within fat and
liver tissue remains the secretion of chemokines, such as
MCP1, Rantes, and others (Weisberg et al., 2006). The signals
that lead to release of these hormones remain unknown, but
Figure 5. Step 4: Counter-Inflammation
One major attribute of inflammation in obesity is that it is sustained and low-
grade. This is due in part to counter-inflammatory pathways that are activated
by cytokines, such as increased expression of the GPR120 receptor for anti-
inflammatory fatty acids. NF-kB activation also increases the expression of the
noncanonical IKKs, IKKε and TBK1, which co-opt insulin signaling pathways to
increase lipogenic and decrease lipolytic programs in the absence of insulin
action.
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interesting possibility is that mechanotransduction pathways
may be involved, particularly in adipose tissue. The extracellular
matrix limits the expansion of fat cells during obesity (Chun et al.,
2006; Kim et al., 2007). Moreover, adipose tissue shows signs of
fibrosis in obese states (Spencer et al., 2011), characterized by
production of collagen VI (Pasarica et al., 2009), andmice lacking
collagen VI becomemorbidly obese on high-fat diet, without any
evidence of inflammation or insulin resistance (Khan et al., 2009).
Thus, it is possible that matrix-dependent signaling senses
a physical limit of fat-cell expansion, initiating activation of path-
ways that lead to chemokine secretion.
It is worth considering that these adaptive immune responses
might be beneficial, and function to preserve metabolic homeo-
stasis, particularly when other adaptive responses, such as
leptin, have failed. Inflammation is generally associated with a
catabolic state, leading to energy mobilization to combat infec-
tion and other stresses. The inflammatory cells that infiltrate liver
and adipose tissue release proinflammatory cytokines that
generally activate catabolic pathways (Figure 4). For example,
TNF-a, originally identified because of its potent catabolic
actions (Torti et al., 1985), can increase lipolysis via MAP kinase
pathways in adipocytes (Souza et al., 2003) while also producing
serine phosphorylation of IRS proteins to block insulin signaling,
using the same pathways involved in homologous desensitiza-
tion. Pattern recognition receptors that might respond to bacte-
rial products or even fatty acids can similarly activate different
MAP kinase pathways (Dunne and O’Neill, 2003). At the same
time, other proinflammatory signaling pathways that have been
implicated in obesity, including ER stress (Hotamisligil, 2010)
and ceramide synthesis (Summers, 2010), as well as JNK and
NF-kB activation (Arkan et al., 2005; Hirosumi et al., 2002), can
potentiate these phosphorylation pathways while promoting
the secretion of more inflammatory cytokines and chemokines
to prolong or amplify inflammatory signals.In addition to correlations between the degree of inflammation
and insulin resistance (OrtegaMartinez de Victoria et al., 2009), it
is also interesting to note that both patients and rodents with the
most extreme forms of obesity can be relatively sensitive to
insulin and, similarly, lack notable signs of inflammation (Bogar-
dus et al., 1985). Likewise, treatment of mice and diabetic
patients with PPARg-activating thiazolidinediones (Patsouris
et al., 2009) or constitutive activation of PPARg in fat cells by
deletion of corepressors (Li et al., 2011b) can block sensing of
proinflammatory signals, as well as recruitment of inflammatory
cells in adipose tissue, whereas activation of this nuclear
receptor is often associated with weight gain and expansion of
adipose tissue (Lu et al., 2011). Taken together, these data
suggest that inflammation may represent another line of defense
against excess nutrient storage, mainly by blocking or counter-
acting insulin action.
Step 4. Counter-Inflammation
The inflammatory response induced by obesity in liver and fat
tissue includes most of the expected cell types, but lacks
many of the cardinal signs of classic inflammation (i.e., dolor,
rubor, calor, tumor). This has led Hotamisligil et al. (Gregor and
Hotamisligil, 2011) to coin the term ‘‘meta-inflammation’’ to
describe the low-grade, sustained nature of obesity-induced
inflammation. How is it that this particular inflammatory response
fails to resolve, and why does the resulting insulin resistance fail
to stop continued energy storage? One possible explanation
may lie in the homeostatic response to inflammation itself, or
counter-inflammation, which attenuates the extent to which
inflammatory signals are effective (Figure 5).
Counter-inflammation can be expressed in different forms. In
the first, classical response, inflammatory pathways can feed-
back-inhibit themselves, toning down their response in a cell-
autonomous manner. This is particularly well established with
the NF-kB and p38 pathways, in which there are feedback
signals that block upstream phosphorylation events in immune
cells (Delhase et al., 1999), particularly involving the TAB/TAK
axis (Clark et al., 2011). During obesity, proinflammatory macro-
phages increase their expression of GPR120, a receptor for anti-
inflammatory omega-3 fatty acids, thus inducing sensitization to
a feedback signal (Oh et al., 2010). There are also genes induced
by NF-kB that can feedback-inhibit the pathway, particularly the
noncanonical kinases IKKε and TBK1 (Kawai and Akira, 2007).
Indeed, macrophages isolated from IKKε knockout mice are
hyperresponsive to activation by TNF-a and LPS (unpublished
data). Additionally, the intriguing and confusing observations
regarding the role of IL-6 in regulating insulin sensitivity may
also reflect a counter-inflammatory process in which IL-6
expression during obesity induces the expression of anti-inflam-
matory cytokines, such as IL-10 (Allen and Febbraio, 2010).
Thus, one intriguing possibility is that these counter-inflamma-
tory processes maintain inflammation in a low-grade state, pro-
hibiting its resolution.
Although counter-inflammatory mechanisms can tone down
inflammation in macrophages, how about the catabolic effects
of inflammatory cytokines in liver and fat cells? Interestingly,
the noncanonical IKKs, IKKε and TBK1, are induced during
obesity but do not appear to function as IkB kinases in this
setting (Chiang et al., 2009). Moreover, anti-inflammatoryCell Metabolism 15, June 6, 2012 ª2012 Elsevier Inc. 801
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expression of these kinases (unpublished data), suggesting
that they are induced by inflammatory cytokines, rather than
participating in inflammation. In this regard, both kinases contain
NF-kB sites in their promoters and are markedly induced by both
TNF and LPS (Kravchenko et al., 2003).
The first clue to the counter-inflammatory role of the nonca-
nonical IKKs came from knockout studies of IKKε. Deletion of
the IKKε gene rendered mice partially resistant to weight gain,
insulin resistance, steatosis, and the long-term inflammation
produced by high-fat diet (Chiang et al., 2009); this has been
reproduced by administration of an IKKε/TBK1 inhibitor to
diet-induced obese or Ob/ob mice (unpublished data). Similar
observations have been made after knockout of the mTORC1
adaptor protein, Raptor (Polak et al., 2008), as well as S6 Kinase
1 (Um et al., 2004). One interpretation of these results is that
different counter-inflammatory events are activated in order to
favor long-term energy conservation. In this regard, insulin
receptor resistance in liver and adipose tissue is often accom-
panied by elevations in basal signaling patterns or expression
of signaling molecules (Wan et al., 2011b; Yang et al., 2003),
and deletion of Akt can prevent obesity by increasing energy
expenditure (Wan et al., 2011a). In liver, the observation of
mixed insulin resistance, in which the antigluconeogenic effects
of insulin are attenuated, whereas while lipogenesis is
preserved, may be an example of this phenomenon (Li et al.,
2010a). Moreover, obesity is associated with desensitization to
sympathetic activation in white and brown fat (Seals and Bell,
2004), resulting in decreased lipolysis and fat oxidation. The
mechanisms underlying these counter-inflammatory changes
are uncertain, but they may also occur as a consequence of
increased nutrient signaling (Wang et al., 2011a). In either event,
the co-opting of anabolic signaling pathways by counter-inflam-
matory kinases like IKKε and TBK1, or nutrient activation of
mTORC1, can generate insulin-independent, constitutive acti-
vation of lipogenic and glycogenic pathways, while subse-
quently promoting feedback inhibition of insulin receptor
signaling. Thus, these insulin-like effects can paradoxically
block insulin action.ShouldWeRethink the Treatment ofMetabolic Disease?
These observations raise important questions about the treat-
ment of obesity and type 2 diabetes. Although there is little doubt
that insulin resistance is a key factor in the generation of type 2
diabetes, it may be overly simplistic to think that merely
improving or mimicking insulin action would provide an effective
solution to this problem. If insulin resistance is indeed a normal
physiological response to overnutrition at the cellular level,
new approaches may be needed to block energy storage or
allow energy utilization as a more effective method to treating
this devastating disease. Although this seems tobe aparadoxical
approach to the treatment of insulin resistance, it may be the
best bet in developing new weapons in the fight against this
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